Updated Labeling for Menopausal Hormone Therapy

This Viewpoint describes the US Food and Drug Administration’s intended label updates and removal of black box warnings for menopausal hormone therapy based on current evidence.

Corresponding Author: Martin A. Makary, MD, MPH, US Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993 (commissionersoffice@fda.hhs.gov).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.